FDA Clears OTC CGM for Non-Insulin-Using Children Aged 2+

Written by The Life Science Feed Editorial Team · Published 14 June 2026 · Edited by Mara Voss

Managing glucose levels in children, particularly those not on insulin therapy, presents a distinct clinical challenge due to the variability in paediatric metabolism and lifestyle. The recent clearance by the US Food and Drug Administration (FDA) of an over-the-counter (OTC) continuous glucose monitor (CGM) for children aged 2 years and older who do not use insulin offers a new tool for monitoring in this population.

KEY TAKEAWAYS

- The Pivot: An OTC CGM is now available for non-insulin-using children as young as 2 years old.
- The Data: The device is indicated for monitoring glucose trends and patterns, and detecting episodes of hypoglycaemia and hyperglycaemia.
- The Action: Clinicians should be aware of this new OTC option for paediatric patients who may benefit from glucose monitoring without a prescription.

Historically, continuous glucose monitoring has primarily been indicated for individuals with diabetes, particularly those on insulin therapy, to optimise glycaemic control and prevent acute complications. The expansion of CGM access to paediatric populations not requiring insulin represents a shift in monitoring strategies. This includes children with prediabetes, those at risk of hypoglycaemia, or those with other conditions where glucose monitoring may provide valuable clinical insights.

The Device and Its Indication

The FDA has granted clearance for an over-the-counter continuous glucose monitor for use in individuals aged 2 years and older who do not use insulin. This device is intended to monitor glucose trends and patterns over time. Its primary functions include the detection of episodes of hypoglycaemia and hyperglycaemia, which can be critical for early intervention and management in paediatric patients. The device is designed to provide real-time glucose readings, offering a more comprehensive picture of glucose dynamics compared to intermittent finger-prick blood glucose testing. The clearance specifies that the device is not intended to replace professional medical advice or to be used for the diagnosis or screening of diabetes. Instead, it serves as an adjunctive tool to support individuals and their caregivers in understanding glucose fluctuations. For children, this can be particularly beneficial in identifying patterns related to diet, physical activity, and other lifestyle factors that influence glucose levels. The availability of an OTC option removes the requirement for a prescription, potentially increasing accessibility for families and caregivers who may benefit from this technology.

The device operates by measuring glucose levels in interstitial fluid via a small sensor inserted under the skin. Data is

transmitted wirelessly to a compatible smart device or reader, allowing for continuous display of glucose values and trend arrows. Alarms can be configured to alert users to high or low glucose levels, providing timely information that can guide immediate actions, such as adjusting food intake or activity. The system is designed for ease of use in a home setting, aligning with its OTC designation. The sensor typically remains in place for several days to two weeks, depending on the specific product, providing continuous data collection over an extended period. This eliminates the need for repeated finger sticks, which can be particularly distressing for young children.

Clinical Context and Potential Impact

The clearance of an OTC CGM for non-insulin-using children aged 2 years and older addresses a previously unmet need in paediatric glucose management. While not a diagnostic tool, it offers a means for proactive monitoring. For children with conditions such as congenital hyperinsulinism, glycogen storage diseases, or those undergoing specific medical treatments that affect glucose metabolism, this device could provide valuable data to clinicians and caregivers. It may also be useful for children with obesity or a strong family history of type 2 diabetes, where early identification of dysglycaemia could inform preventative strategies. The rising prevalence of childhood obesity and associated metabolic risks underscores the importance of tools that can aid in early detection and intervention for glucose dysregulation. The data collected by such devices can facilitate more informed discussions between families and healthcare providers regarding lifestyle modifications, nutritional guidance, and the timing of medical interventions. The ability to track glucose patterns without the need for frequent clinic visits or prescription renewals simplifies the monitoring process. However, it is imperative that caregivers understand the limitations of OTC devices and continue to engage with healthcare professionals for interpretation of data and clinical decision-making. The device's role is to provide information, not to dictate treatment protocols independently. Caregivers must be educated on how to interpret the data, recognize potential sensor inaccuracies, and understand when to seek professional medical advice. Furthermore, the psychological impact of continuous monitoring on children and families, while potentially beneficial, also warrants consideration and appropriate support from healthcare providers.

CLINICAL IMPLICATIONS

The FDA's clearance of an OTC continuous glucose monitor for non-insulin-using children aged 2 years and older marks a significant shift in paediatric glucose management. Clinicians should anticipate an increase in patient and caregiver inquiries regarding this technology. While not a diagnostic tool, its utility in providing real-time glucose trend data for conditions like prediabetes, risk of hypoglycaemia, or other metabolic concerns cannot be understated. The absence of a prescription barrier will undoubtedly broaden access, placing a greater onus on primary care physicians and paediatricians to interpret the data effectively and counsel families on its appropriate use and limitations.

For the industry, this move by the FDA signals a growing market for consumer-friendly medical devices beyond traditional disease management. Companies developing similar technologies will likely accelerate their efforts to capture this expanding demographic. The challenge will be to balance accessibility with clinical accuracy and to ensure that the data generated is actionable and does not lead to unnecessary anxiety or misinterpretation by non-medical users. The success of this OTC CGM will likely pave the way for further innovation in self-monitoring tools for various health parameters.

> Patients and their families stand to benefit from enhanced awareness and proactive management of glucose fluctuations, particularly in scenarios where frequent clinic visits or invasive testing are impractical. However, it is critical that this convenience does not overshadow the need for professional medical guidance. The device provides data, but the clinical context and interpretation remain the domain of the healthcare provider. Education on when to seek medical advice based on CGM readings will be paramount to prevent self-diagnosis or inappropriate interventions, ensuring that this technological advancement truly serves to improve paediatric health outcomes.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. FDA. FDA Clears First Over-the-Counter Continuous Glucose Monitor for Children. Accessed Jun 2026. http://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor-children

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com